glp 1 agonist anti inflammatory Frontiers Frontiers | GLP-1 Receptor Agonists:

Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk

These factors, along with proven efficacy in glycemic control, weight management, and cardiovascular risk reduction, make Europe a key region for the growth and adoption of GLP-1 therapies

Diabetes and GLP-1 RA Use in Cancer Incidence Beyond weight loss, GLP-1 RAs appear to have a protective effect against cancer development and progression

Author Contributions All authors contributed to the following during the development of this article: conception and design

Keywords: glucagon-like peptide-1 receptor agonist, obesity, type 2 diabetes, gastrointestinal adverse events Introduction Diabetes and obesity are increasing at an alarming rate worldwide and placing a significant burden on global healthcare systems